INDOBUFEN VERSUS ASPIRIN PLUS DIPYRIDAMOLE AFTER CORONARY-ARTERY BYPASS-SURGERY

被引：0

作者：

ROVELLI, F ^{[1
]}

CAMPOLO, L ^{[1
]}

CATALDO, G ^{[1
]}

PELLEGRINI, A ^{[1
]}

MANNUCCI, PM ^{[1
]}

MARUBINI, E ^{[1
]}

DEGAETANO, G ^{[1
]}

ORZAN, F ^{[1
]}

CATALDO, G ^{[1
]}

LAVEZZARI, M ^{[1
]}

PETROCCIONE, A ^{[1
]}

PIROTTA, N ^{[1
]}

BERTELE, V ^{[1
]}

CATTANEO, M ^{[1
]}

MILANESI, G ^{[1
]}

MONTORO, C ^{[1
]}

PAMPARANA, F ^{[1
]}

PANZERI, E ^{[1
]}

SACCHETTI, G ^{[1
]}

DANZI, GB ^{[1
]}

ROGHI, A ^{[1
]}

OGGIONI, E ^{[1
]}

GALEAZZI, M ^{[1
]}

MAGNANI, B ^{[1
]}

MANTOVANI, B ^{[1
]}

PIERANGELI, A ^{[1
]}

SANGUINETTI, M ^{[1
]}

GIORDANO, D ^{[1
]}

INVERNIZZI, G ^{[1
]}

PARENZAN, L ^{[1
]}

VALSECCHI, O ^{[1
]}

ALFIERI, O ^{[1
]}

ETTORI, F ^{[1
]}

NICCOLI, L ^{[1
]}

PARDINI, A ^{[1
]}

RAMBALDINI, M ^{[1
]}

VISIOLI, O ^{[1
]}

ABBATE, M ^{[1
]}

CALVI, V ^{[1
]}

CARLI, L ^{[1
]}

LICCIARDELLO, G ^{[1
]}

MEO, L ^{[1
]}

MILLAN, G ^{[1
]}

BADANO, L ^{[1
]}

GATTO, E ^{[1
]}

MICCOLI, F ^{[1
]}

SPAGNOLO, S ^{[1
]}

BELLUZZI, F ^{[1
]}

BONI, G ^{[1
]}

COLUCCI, C ^{[1
]}

机构：

[1] OSPED NIGUARDA CA GRANDA,PIAZZA OSPED MAGGIORE 3,I-20162 MILAN,ITALY

来源：

CORONARY ARTERY DISEASE | 1991年 / 2卷 / 08期

关键词：

SURGERY; CORONARY ARTERY BYPASS; GRAFT OCCLUSION; VASCULAR PATENCY; PLATELET AGGREGATION INHIBITORS; ASPIRIN; DIPYRIDAMOLE;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To compare the effects of indobufen with those of acetylsalicylic acid (aspirin) plus dipyridamole on graft patency, 569 patients undergoing coronary artery bypass surgery in 19 centers were randomly and blindly assigned to treatment with indobufen (400 mg daily) or with aspirin (975 mg daily) plus dipyridamole (225 mg daily). All the patients were treated with 100 mg dipyridamole four times daily preoperatively. Administration of medication began 6 hours after surgery. During the first 2 postoperative days the drugs were given intravenously (dipyridamole plus aspirin at lower doses). Graft patency was assessed by angiography soon after (median, 15 days) and 1 year after surgery. Baseline characteristics of the treatment groups were comparable. No significant differences were found between the treatment groups in the proportion of patients with one or more occluded grafts (early: 22.7% indobufen vs 23.4% aspirin plus dipyridamole; 1 year: 34.2% indobufen vs 34.4% aspirin plus dipyridamole) or in the proportion of occluded distal anastomoses (early: 10.0% indobufen vs 11.1% aspirin plus dipyridamole; 1 year: 16.9% indobufen vs 18.9% aspirin plus dipyridamole). Adverse drug reactions chiefly involved the gastrointestinal tract and occurred in 27 of 290 patients in the indobufen group and in 50 of 279 in the aspirin plus dipyridamole group (P < 0.01). Gastrointestinal adverse reactions included bleeding in two and 17 patients, respectively. The study shows that indobufen (200 mg twice daily) is at least as effective as and is safer than a regimen of 325 mg aspirin plus 75 mg dipyridamole three times daily in preventing graft occlusion.

引用

页码：897 / 906

页数：10

共 32 条

[21]

LAVEZZARI M, 1989, CURR THER RES CLIN E, V46, P19

[22] VEIN GRAFT PATENCY AND INTIMAL PROLIFERATION AFTER AORTOCORONARY BYPASS - EARLY AND LONG-TERM ANGIOPATHOLOGIC CORRELATIONS [J].

LAWRIE, GM ;

LIE, JT ;

MORRIS, GC ;

BEAZLEY, HL .

AMERICAN JOURNAL OF CARDIOLOGY, 1976, 38 (07) :856-862

[23]

LIMET R, 1987, J THORAC CARDIOV SUR, V94, P773

[24]

LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248

[25] INDOBUFEN IS A POTENT INHIBITOR OF WHOLE-BLOOD AGGREGATION IN PATIENTS WITH A HIGH ATHEROSCLEROTIC RISK [J].

MANNUCCI, L ;

MADERNA, P ;

COLLI, S ;

LAVEZZARI, M ;

SIRTORI, CR ;

TREMOLI, E .

THROMBOSIS RESEARCH, 1987, 48 (04) :417-426

[26]

MANTEL N, 1959, J NATL CANCER I, V22, P719

[27] A LINEAR-MODEL SUITABLE FOR ASSESSING GRAFT PATENCY IN CONTROLLED CLINICAL-TRIALS [J].

MARUBINI, E ;

MONTORO, C ;

MEZZANOTTE, G ;

PETROCCIONE, A ;

CATALDO, G ;

ROVELLI, F .

CONTROLLED CLINICAL TRIALS, 1990, 11 (06) :420-432

[28]

MCENANY MT, 1982, J THORAC CARDIOV SUR, V83, P81

[29] THE CHANGING PROFILE OF THE PATIENT UNDERGOING CORONARY-ARTERY BYPASS-SURGERY [J].

NAUNHEIM, KS ;

FIORE, AC ;

WADLEY, JJ ;

MCBRIDE, LR ;

KANTER, KR ;

PENNINGTON, DG ;

BARNER, HB ;

KAISER, GC ;

WILLMAN, VL .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 11 (03) :494-498

[30] PREVENTION OF EARLY AORTOCORONARY BYPASS OCCLUSION BY LOW-DOSE ASPIRIN AND DIPYRIDAMOLE [J].

SANZ, G ;

PAJARON, A ;

ALEGRIA, E ;

COELLO, I ;

CARDONA, M ;

FOURNIER, JA ;

GOMEZRECIO, M ;

RUANO, J ;

HIDALGO, R ;

MEDINA, A ;

OLLER, G ;

COLMAN, T ;

MALPARTIDA, F ;

BOSCH, X .

CIRCULATION, 1990, 82 (03) :765-773

← 1 2 3 4 →